Disease overview Chronic lymphocytic leukemia (CLL) is one of the most frequent types of
leukemia. It typically occurs in elderly patients and has a highly variable clinical course …

Adoptive T cell transfer (ACT) is a new area of transfusion medicine involving the infusion of
lymphocytes to mediate antitumor, antiviral, or anti-inflammatory effects. The field has rapidly …

Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established
efficacy, and a favorable and well-defined safety profile in patients with various CD20 …

Genetically engineered T cells are powerful new medicines, offering hope for curative
responses in patients with cancer. Chimeric antigen receptor (CAR) T cells were recently …

Globally, annual spending on anticancer drugs is around US $100 billion, and is predicted
to rise to $150 billion by 2020. In the USA, a novel anticancer drug routinely costs more than …

Purpose The MURANO study demonstrated significant progression-free survival (PFS)
benefit for fixed-duration venetoclax-rituximab compared with bendamustine-rituximab in …

Disease overview Chronic lymphocytic leukemia (CLL) is the commonest leukemia in
western countries. The disease typically occurs in elderly patients and has a highly variable …

Background The treatment landscape for chronic lymphocytic leukemia (CLL) continues to
undergo considerable evolution. Optimal selection of initial therapy from multiple effective …

Ibrutinib is highly efficacious and used at 420 mg/d for treatment of chronic lymphocytic
leukemia (CLL). We previously demonstrated a decline in Bruton's tyrosine kinase (BTK) …

Tremendous progress in treatment and outcomes has been achieved across the whole
range of haematological malignancies in the past two decades. Although cure rates for …